These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 27646589)

  • 41. Intravenous IgG (IVIG) and subcutaneous IgG (SCIG) preparations have comparable inhibitory effect on T cell activation, which is not dependent on IgG sialylation, monocytes or B cells.
    Issekutz AC; Rowter D; Miescher S; Käsermann F
    Clin Immunol; 2015 Oct; 160(2):123-32. PubMed ID: 25982320
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Contamination of IgG preparation for intravenous use with IgA. II. Removal of IgA1 from IgG preparation using affinity chomatography on lectin jacalin columns].
    Dovezenski N; Velicković Z; Tosić Lj; Nikolić G; Popović O; Romić M; Djokić M; Mijusković Z
    Srp Arh Celok Lek; 1994; 122 Suppl 1():51-2. PubMed ID: 18173187
    [TBL] [Abstract][Full Text] [Related]  

  • 43. International collaborative study to evaluate candidate reference reagents to standardize haemagglutination testing for anti-A and anti-B in normal intravenous immunoglobulin products.
    Thorpe SJ; Fox B; Sharp G; Heath AB; Behr-Gross ME; Terao E; Virata-Theimer ML; Yu MW
    Vox Sang; 2009 Aug; 97(2):160-8. PubMed ID: 19402856
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reduction of anti-A and anti-B isoagglutinin titers of group O whole blood units employing an ABO antibody immune adsorption column.
    Gupta GK; Henrichs K; Nilsson K; Wagner S; Brown B; Masel D; Gestring ML; Vella MA; Refaai MA; Blumberg N
    Transfus Apher Sci; 2023 Jun; 62(3):103686. PubMed ID: 36894466
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Therapeutic plasma exchange as a therapeutic modality for the treatment of IVIG complications.
    Welsh KJ; Bai Y
    J Clin Apher; 2015 Dec; 30(6):371-4. PubMed ID: 26123478
    [TBL] [Abstract][Full Text] [Related]  

  • 46. ABO-incompatible living donor liver transplantation is suitable in patients without ABO-matched donor.
    Kim JM; Kwon CH; Joh JW; Kang ES; Park JB; Lee JH; Kim SJ; Paik SW; Lee SK; Kim DW
    J Hepatol; 2013 Dec; 59(6):1215-22. PubMed ID: 23928408
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Quantification of blood group A and B antibodies by flow cytometry using beads carrying A or B trisaccharides.
    Sundbäck M; Grufman P; Teller J; Westphal F; Korchagina E; Bovin N; Holgersson J
    Transplantation; 2007 Dec; 84(12 Suppl):S24-6. PubMed ID: 18162983
    [TBL] [Abstract][Full Text] [Related]  

  • 48. ABO blood group IgM isoagglutinins interact with tumor-associated O-glycan structures in pancreatic cancer.
    Hofmann BT; Stehr A; Dohrmann T; Güngör C; Herich L; Hiller J; Harder S; Ewald F; Gebauer F; Tachezy M; Precht C; Izbicki JR; Bockhorn M; Wagener C; Wolters-Eisfeld G
    Clin Cancer Res; 2014 Dec; 20(23):6117-26. PubMed ID: 25320359
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Randomized trial of anti-D immunoglobulin versus low-dose intravenous immunoglobulin in the treatment of childhood chronic idiopathic thrombocytopenic purpura.
    El Alfy MS; Mokhtar GM; El-Laboudy MA; Khalifa AS
    Acta Haematol; 2006; 115(1-2):46-52. PubMed ID: 16424649
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Heart transplantation across antibodies against human leukocyte antigen and ABO-post-transplant follow-up of donor reactive antibodies.
    Bućin D; Johansson S; Lindberg LO
    Xenotransplantation; 2006 Mar; 13(2):101-4. PubMed ID: 16623800
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Preparation of lyophilized and liquid intravenous immunoglobulin G: development and scale-up.
    Sisti AM; Vitali MS; Manfredi MJ; Zarzur JA
    Vox Sang; 2001 May; 80(4):216-24. PubMed ID: 11438029
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A 10% liquid immunoglobulin preparation for intravenous use (Privigen®) in paediatric patients with primary immunodeficiencies and hypersensitivity to IVIG.
    Lozano-Blasco J; Martín-Mateos MA; Alsina L; Domínguez O; Giner MT; Piquer M; Alvaro M; Plaza AM
    Allergol Immunopathol (Madr); 2014; 42(2):136-41. PubMed ID: 23253680
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pneumococcal antibody levels in children with PID receiving immunoglobulin.
    Tuerlinckx D; Florkin B; Ferster A; De Schutter I; Chantrain C; Haerynck F; Philippet P; Strengers P; Laub R
    Pediatrics; 2014 Jan; 133(1):e154-62. PubMed ID: 24366995
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Outcome of desensitization in human leukocyte antigen- and ABO-incompatible living donor kidney transplantation: a single-center experience in more than 100 patients.
    Al Meshari K; Pall A; Chaballout A; El Gamal H; Al Mana H; Humaidan H; Alzayer F; Al Talhi M
    Transplant Proc; 2013 May; 45(4):1423-6. PubMed ID: 23726587
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Specifications for anti-A and anti-B in intravenous immunoglobulin: history and rationale.
    Thorpe SJ
    Transfusion; 2015 Jul; 55 Suppl 2():S80-5. PubMed ID: 26174902
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Kinetics of anti-blood type isoagglutinin titers and B lymphocytes in ABO-incompatible living donor liver transplantation with rituximab and plasma exchange.
    Uchiyama H; Mano Y; Taketomi A; Soejima Y; Yoshizumi T; Ikegami T; Shirabe K; Maehara Y
    Transplantation; 2011 Nov; 92(10):1134-9. PubMed ID: 21946174
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Purification of intravenous immunoglobulin G from human plasma--aspects of yield and virus safety.
    Buchacher A; Iberer G
    Biotechnol J; 2006 Feb; 1(2):148-63. PubMed ID: 16892245
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of human intravenous immunoglobulin on canine monocytes and lymphocytes.
    Reagan WJ; Scott-Moncrieff C; Christian J; Snyder P; Kelly K; Glickman L
    Am J Vet Res; 1998 Dec; 59(12):1568-74. PubMed ID: 9858408
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biochemical Characterization of a New 10% IVIG Preparation [IgG Next Generation (BT595)/Yimmugo
    Duellberg C; Hannappel A; Kistner S; Maneg O
    Drugs R D; 2023 Sep; 23(3):245-255. PubMed ID: 37466834
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hemolytic anemia following high dose intravenous immunoglobulin in patients with chronic neurological disorders.
    Markvardsen LH; Christiansen I; Harbo T; Jakobsen J
    Eur J Neurol; 2014; 21(1):147-52. PubMed ID: 24180709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.